Enzymes are involved in catalyzing various metabolic and regulatory pathways of life, and are related to various diseases. Therefore, targeting enzymes has become a popular drug development direction for current biopharmaceutical companies. CD BioSciences provides comprehensive enzyme-targeted peptidomimetic development services dedicated to helping clients achieve the best results.
Overview of Enzymes
Enzymes are a class of biological catalysts, they govern many catalytic processes such as metabolism, nutrition and energy conversion of organisms. Enzymes enable the intricate material metabolism processes in cells to proceed in an orderly manner. If a certain enzyme is defective due to genetic defects, or other reasons, the weakening of the activity of the enzyme can lead to abnormal reactions catalyzed by the enzyme, disorder of material metabolism, and even disease. Therefore, the relationship between enzymes and medicine is very close.
Fig. 1 Classification of Enzymes.
Advantages of Peptidomimetic Development
Since the discovery of the human immunodeficiency virus (HIV) protease, peptide inhibitors targeting this enzyme have developed rapidly. Currently, peptide drugs developed with enzymes as targets occupy most of the market. However, one of the problems with these drugs is their poor stability, making it difficult to fully achieve their goals and exert their efficacy. The development of peptidomimetic just solves the above-mentioned problems. By introducing stable amino acids and screening for protease resistance, higher stability can be obtained. In addition, some structural modifications can also improve the in vivo half-life of peptidomimetics. In conclusion, the development of these peptidomimetics will greatly facilitate the research progress of enzyme-targeted peptide drugs.
Fig. 2 HIV proteases mature HIV virions, and inhibitors of HIV proteolytic enzymes prevent this maturation. (Kenakin T P, 2017)
Our Service
CD Biosciences provides global customers with comprehensive services for the development of peptidomimetics targeting multiple types of enzymes, helping you make faster progress in scientific research and new drug discovery. Our service areas are as follows:
De novo Peptidomimetics Development Service
Our PepDomTM platform conducts high-throughput screening by establishing a diverse peptidomimetic library to identify peptidomimetic molecules that bind to the target enzyme and further optimize the resistance, and finally isolate and purify the ideal peptidomimetic compound targeting the target enzyme. Our platform can provide novel target options for the development of enzyme inhibitors based on fragment-based lead discovery and screening of nucleic acid-encoded chemical libraries.
Peptidomimetics Optimization Service
Our PepDomTM platform can reasonably develop and optimize peptidomimetic based on the transition state of enzyme catalyzed chemical reactions. The designed peptidomimetics are usually very similar to the target enzyme substrate, but part of the structure of the substrate is modified and optimized into a transitional state. In this way, we can obtain peptidomimetics with higher affinity than the substrate.
Features of Our Service
We are committed to helping customers innovate research results in the field of enzyme-targeted peptidomimetics development.
Industrial Leadership
Customer First
Cost Efficient
Highly Customizable
CD BioSciences stands ready to provide the best possible service to each of our customers. As long as you provide information about any target enzyme you are interested in, our professionals will contact you immediately to prepare the optimal development plan for you. Welcome to contact us!
References
- Kenakin, T. P. (2017). Enzymes as drug targets. Pharmacology in Drug Discovery and Development (Second Edition), 131-156.
- Lenci, E., & Trabocchi, A. (2020). Peptidomimetic toolbox for drug discovery. Chemical Society Reviews, 49(11): 3262-3277.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
